69 related articles for article (PubMed ID: 15815724)
1. Imatinib induces apoptosis in CLL lymphocytes with high expression of Par-4.
Chow KU; Nowak D; Hofmann W; Schneider B; Hofmann WK
Leukemia; 2005 Jun; 19(6):1103-5; author reply 1105-6; discussion 1106-7. PubMed ID: 15815724
[No Abstract] [Full Text] [Related]
2. In bcr-abl-positive myeloid cells resistant to conventional chemotherapeutic agents, expression of Par-4 increases sensitivity to imatinib (STI571) and histone deacetylase-inhibitors.
Brieger A; Boehrer S; Schaaf S; Nowak D; Ruthardt M; Kim SZ; Atadja P; Hoelzer D; Mitrou PS; Weidmann E; Chow KU
Biochem Pharmacol; 2004 Jul; 68(1):85-93. PubMed ID: 15183120
[TBL] [Abstract][Full Text] [Related]
3. c-Abl expression in chronic lymphocytic leukemia cells: clinical and therapeutic implications.
Lin K; Glenn MA; Harris RJ; Duckworth AD; Dennett S; Cawley JC; Zuzel M; Slupsky JR
Cancer Res; 2006 Aug; 66(15):7801-9. PubMed ID: 16885384
[TBL] [Abstract][Full Text] [Related]
4. Imatinib sensitizes CLL lymphocytes to chlorambucil.
Aloyz R; Grzywacz K; Xu ZY; Loignon M; Alaoui-Jamali MA; Panasci L
Leukemia; 2004 Mar; 18(3):409-14. PubMed ID: 14712290
[TBL] [Abstract][Full Text] [Related]
5. Erythropoietin overcomes imatinib-induced apoptosis and induces erythroid differentiation in TF-1/bcr-abl cells.
Uchida M; Watanabe T; Kunitama M; Mori M; Kikuchi S; Yoshida K; Kirito K; Nagai T; Ozawa K; Komatsu N
Stem Cells; 2004; 22(4):609-16. PubMed ID: 15277706
[TBL] [Abstract][Full Text] [Related]
6. Activation of STAT5 confers imatinib resistance on leukemic cells through the transcription of TERT and MDR1.
Yamada O; Ozaki K; Furukawa T; Machida M; Wang YH; Motoji T; Mitsuishi T; Akiyama M; Yamada H; Kawauchi K; Matsuoka R
Cell Signal; 2011 Jul; 23(7):1119-27. PubMed ID: 21356308
[TBL] [Abstract][Full Text] [Related]
7. A phase I study of imatinib mesylate in combination with chlorambucil in previously treated chronic lymphocytic leukemia patients.
Hebb J; Assouline S; Rousseau C; Desjardins P; Caplan S; Egorin MJ; Amrein L; Aloyz R; Panasci L
Cancer Chemother Pharmacol; 2011 Sep; 68(3):643-51. PubMed ID: 21120481
[TBL] [Abstract][Full Text] [Related]
8. N-(4-hydroxyphenyl)retinamide promotes apoptosis of resting and proliferating B-cell chronic lymphocytic leukemia cells and potentiates fludarabine and ABT-737 cytotoxicity.
Bruno S; Ghiotto F; Tenca C; Mazzarello AN; Bono M; Luzzi P; Casciaro S; Recchia A; Decensi A; Morabito F; Fais F
Leukemia; 2012 Oct; 26(10):2260-8. PubMed ID: 22475870
[TBL] [Abstract][Full Text] [Related]
9. Overproduction of BCR-ABL induces apoptosis in imatinib mesylate-resistant cell lines.
Desplat V; Belloc F; Lagarde V; Boyer C; Melo JV; Reiffers J; Praloran V; Mahon FX
Cancer; 2005 Jan; 103(1):102-10. PubMed ID: 15558795
[TBL] [Abstract][Full Text] [Related]
10. Imatinib enhances human melanoma cell susceptibility to TRAIL-induced cell death: Relationship to Bcl-2 family and caspase activation.
Hamaï A; Richon C; Meslin F; Faure F; Kauffmann A; Lecluse Y; Jalil A; Larue L; Avril MF; Chouaib S; Mehrpour M
Oncogene; 2006 Dec; 25(58):7618-34. PubMed ID: 16983347
[TBL] [Abstract][Full Text] [Related]
11. Imatinib (STI571) induces DNA damage in BCR/ABL-expressing leukemic cells but not in normal lymphocytes.
Czechowska A; Poplawski T; Drzewoski J; Blasiak J
Chem Biol Interact; 2005 Apr; 152(2-3):139-50. PubMed ID: 15840387
[TBL] [Abstract][Full Text] [Related]
12. Histone deacetylase inhibitor LAQ824 both lowers expression and promotes proteasomal degradation of Bcr-Abl and induces apoptosis of imatinib mesylate-sensitive or -refractory chronic myelogenous leukemia-blast crisis cells.
Nimmanapalli R; Fuino L; Bali P; Gasparetto M; Glozak M; Tao J; Moscinski L; Smith C; Wu J; Jove R; Atadja P; Bhalla K
Cancer Res; 2003 Aug; 63(16):5126-35. PubMed ID: 12941844
[TBL] [Abstract][Full Text] [Related]
13. Amiloride modulates alternative splicing in leukemic cells and resensitizes Bcr-AblT315I mutant cells to imatinib.
Chang WH; Liu TC; Yang WK; Lee CC; Lin YH; Chen TY; Chang JG
Cancer Res; 2011 Jan; 71(2):383-92. PubMed ID: 21224352
[TBL] [Abstract][Full Text] [Related]
14. Persistent activation of the Fyn/ERK kinase signaling axis mediates imatinib resistance in chronic myelogenous leukemia cells through upregulation of intracellular SPARC.
Fenouille N; Puissant A; Dufies M; Robert G; Jacquel A; Ohanna M; Deckert M; Pasquet JM; Mahon FX; Cassuto JP; Raynaud S; Tartare-Deckert S; Auberger P
Cancer Res; 2010 Dec; 70(23):9659-70. PubMed ID: 21098700
[TBL] [Abstract][Full Text] [Related]
15. Imatinib mesylate induces quiescence in gastrointestinal stromal tumor cells through the CDH1-SKP2-p27Kip1 signaling axis.
Liu Y; Perdreau SA; Chatterjee P; Wang L; Kuan SF; Duensing A
Cancer Res; 2008 Nov; 68(21):9015-23. PubMed ID: 18974147
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of potassium currents as a pharmacologic target for investigation in chronic lymphocytic leukemia.
Biderman B; Marakhonov A; Skoblov M; Birerdinc A; Nohelty E; Page S; Khomenkov V; Chandhoke V; Sudarikov A; Nikitin E; Baranova A
Drug News Perspect; 2010 Dec; 23(10):625-31. PubMed ID: 21180648
[TBL] [Abstract][Full Text] [Related]
17. ZRF4, a combi-molecule with increased efficacy as compared with the individual components in chronic lymphocytic leukemia lymphocytes in vitro.
Amrein L; Rachid Z; Jean-Claude B; Soulières D; Aloyz R; Panasci L
Leukemia; 2011 Sep; 25(9):1512-6. PubMed ID: 21647162
[No Abstract] [Full Text] [Related]
18. Effects of the proteasome inhibitor, bortezomib, on apoptosis in isolated lymphocytes obtained from patients with chronic lymphocytic leukemia.
Pahler JC; Ruiz S; Niemer I; Calvert LR; Andreeff M; Keating M; Faderl S; McConkey DJ
Clin Cancer Res; 2003 Oct; 9(12):4570-7. PubMed ID: 14555532
[TBL] [Abstract][Full Text] [Related]
19. Ceramide-induced killing of normal and malignant human lymphocytes is by a non-apoptotic mechanism.
Mengubas K; Riordan FA; Bravery CA; Lewin J; Owens DL; Mehta AB; Hoffbrand AV; Wickremasinghe RG
Oncogene; 1999 Apr; 18(15):2499-506. PubMed ID: 10229201
[TBL] [Abstract][Full Text] [Related]
20. Changes in cell adhesivity and cytoskeleton-related proteins during imatinib-induced apoptosis of leukemic JURL-MK1 cells.
Kuželová K; Pluskalová M; Grebeňová D; Pavlásková K; Halada P; Hrkal Z
J Cell Biochem; 2010 Dec; 111(6):1413-25. PubMed ID: 20830748
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]